Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) specializes in diabetes management solutions like insulin pumps and related technologies. The stock showed significant bullish activity today.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.1% on Jan 21, 2026 16:10

• TNDM's stock price has increased by 36.3% in the last three months despite previous declines, which likely contributed to today's positive movement.
• An inquiry into potential securities claims against TNDM and concerns about misleading business information may have led to an initial stock price drop. However, today's market response suggests growing confidence in the company's future.
• Issues with certain t:slim X2 insulin pumps resulted in a significant stock decrease, causing investor unease. The subsequent recovery indicates a reevaluation of the pumps' impact on TNDM's performance.
• Analysts considering TNDM undervalued and providing fair value estimates based on projected growth and product advancements possibly influenced today's bullish activity, reflecting investor optimism about the company's future prospects.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

A Look At Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Recovery

Tandem Diabetes Care (TNDM) has experienced a recent stock price recovery, gaining 36.3% over the past three months despite longer-term declines. The company reported revenue of US$1,007.001m and a net loss of US$203.366m. Analysts currently view TNDM as 21.6% undervalued, with a fair value estimate of US$25.71 per share, based on anticipated growth, profitability, and product advancements.

https://www.sahmcapital.com/news/content/a-look-at-tandem-diabetes-care-tndm-valuation-after-recent-share-price-recovery-2026-01-17

Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

The Rosen Law Firm is investigating potential securities claims on behalf of investors in Tandem Diabetes Care, Inc. (TNDM) following allegations that the company issued materially misleading business information. This investigation stems from a voluntary medical device correction announced on August 7, 2025, for certain t:slim X2 insulin pumps, which led to a 19.9% drop in the company's stock. Investors affected are encouraged to contact the firm to inquire about joining a prospective class action lawsuit.

https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation--tndm-302663773.html

Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (TNDM) following allegations that the company issued misleading business information. This investigation stems from a voluntary medical device correction announced on August 7, 2025, which caused the stock to drop by 19.9% due to a speaker-related issue in t:slim X2 insulin pumps leading to potential insulin delivery discontinuation. Investors who purchased Tandem Diabetes securities are encouraged to contact the law firm to learn about joining a prospective class action to recover losses.

https://www.barchart.com/story/news/37092918/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation-tndm

Trending Today

Internet Computer ($ICP) Crypto Forecast: Down 5.0% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 7.7% Today

Mobileye Global ($MBLY) Stock Forecast: Down 7.0% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 5.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 10.7% Today

Intel Corporation ($INTC) Stock Forecast: Down 17.6% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Up 4.9% Today

Sonos Inc. ($SONO) Stock Forecast: Down 5.2% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 8.0% Today

Leggett & Platt Incorporated ($LEG) Stock Forecast: Down 5.2% Today

Tandem Diabetes Care, Inc. Price History

21.00.2026 - TNDM Stock was up 5.1%

• TNDM's stock price has increased by 36.3% in the last three months despite previous declines, which likely contributed to today's positive movement.
• An inquiry into potential securities claims against TNDM and concerns about misleading business information may have led to an initial stock price drop. However, today's market response suggests growing confidence in the company's future.
• Issues with certain t:slim X2 insulin pumps resulted in a significant stock decrease, causing investor unease. The subsequent recovery indicates a reevaluation of the pumps' impact on TNDM's performance.
• Analysts considering TNDM undervalued and providing fair value estimates based on projected growth and product advancements possibly influenced today's bullish activity, reflecting investor optimism about the company's future prospects.

13.00.2026 - TNDM Stock was down 5.1%

• Despite reporting a loss in Q3, Tandem Diabetes Care surpassed revenue expectations, showcasing resilience amid market challenges. The wider loss possibly influenced the downturn in the stock price.
• Speculation surrounding the forthcoming Q4 earnings report, which is anticipated to show a revenue decrease and increased loss, might have impacted the stock negatively.
• Investor concern persists regarding Tandem Diabetes Care's struggle with profitability, awaiting the company's future guidance and growth strategies following the Q4 financial results disclosure.
• The market's response to the news of the upcoming financial results release on February 19, 2026, potentially prompted profit-taking and selling activity, driving the bearish trend in TNDM stock.

22.11.2025 - TNDM Stock was up 5.1%

• The bullish movement in TNDM stock could be attributed to the recent launch of the t:slim mobile application in Canada, expanding the company's reach and enhancing its integrated diabetes management solutions.
• Despite challenges with a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue, the stock managed to rebound, possibly due to a recent upgrade of Tandem Diabetes Care, reflecting an improved outlook for the company.
• Ongoing investigations by a law firm regarding potential securities claims and class action lawsuits might have initially caused a drop in the stock price, but the market's positive response to the company's product expansion and analyst upgrade helped drive the bullish movement.

31.09.2025 - TNDM Stock was down 6.9%

• The bearish movement in TNDM's stock today may be linked to the announcement of a securities class action investigation by a law firm. Concerns among investors about potential legal implications possibly triggered a sell-off.
• Despite anticipated outperformance in earnings estimates for the upcoming period, uncertainties related to the investigation might have outweighed any positive outlook, resulting in a negative investor sentiment.
• The current mix of positive earnings expectations and legal concerns has generated a varied sentiment, contributing to a bearish trend for TNDM's stock today.

09.00.2026 - TNDM Stock was down 9.7%

• Today's downward movement in TNDM stock could be tied to market expectations for the upcoming Q4 2025 earnings. Analysts foresee a decline in revenue and a wider loss compared to the previous year. Key metrics such as gross margin, pump shipments, and international sales are closely watched, prompting investors to review their positions. Concerns about the company's market position and growth strategies might have shifted market sentiment, leading to a stock sell-off.

10.09.2025 - TNDM Stock was down 5.2%

• A securities class action investigation could have raised concerns among investors, leading to a sell-off of TNDM shares.
• Investor uncertainty regarding the potential outcomes of the investigation might have contributed to the bearish movement in TNDM stock.
• The negative sentiment surrounding the company due to the ongoing legal scrutiny could have overshadowed any positive developments, impacting the stock price negatively.

04.10.2025 - TNDM Stock was up 5.2%

• The bullish movement in TNDM stock today could be attributed to the anticipation of beating earnings estimates in the upcoming report.
• The news of a securities class action investigation might have initially caused some uncertainty in the market, but investors seem to have focused more on the positive expectations for the earnings report.
• Investors may be optimistic about Tandem Diabetes Care's potential for strong financial performance, leading to increased buying interest and driving the stock price higher.
• Overall, the market movement reflects a mix of short-term concerns regarding the investigation and long-term confidence in the company's earnings potential, resulting in a bullish sentiment for TNDM stock.

16.11.2025 - TNDM Stock was up 6.4%

• The company was upgraded to "Outperform" from "Neutral" by Baird, accompanied by an increased price target. This adjustment signals a favorable outlook on the company's financial future, potentially contributing to the upward movement.
• A previous investigation into a securities class action following a stock decline due to a voluntary medical device correction may have led to initial uncertainty and a decrease in the stock price. However, the subsequent positive outlook and upgrade likely played a role in driving the upward movement.
• While concerns existed regarding pump demand and negative EBITDA, the recent price surge and a possible undervaluation, as indicated by Simply Wall St's DCF model, could have attracted investors, thereby leading to the uptrend.
• In summary, a combination of optimistic analyst assessments, potential undervaluation, and anticipated future growth opportunities probably fueled today's upward movement in Tandem Diabetes Care's stock.

16.00.2026 - TNDM Stock was up 5.3%

• TNDM exceeded revenue expectations in Q3 despite facing a loss, demonstrating resilience amid market challenges.
• Analysts' consensus "Hold" rating on TNDM reflects a cautious outlook on the stock.
• Noteworthy institutional investors such as Assenagon Asset Management S.A. acquiring a considerable stake in TNDM may have fueled the bullish trend, indicating confidence in the company's future.
• AI-generated trading strategies have hinted at potential downside risks, causing some investors to consider this alongside TNDM's positive revenue performance.

20.10.2025 - TNDM Stock was up 5.0%

• Investor optimism regarding TNDM stock is likely due to the recent news of an investigation by the Rosen Law Firm into potential securities claims on behalf of shareholders.
• This development may have boosted investor confidence in the company's outlook.
• The market's reaction suggests that investors are hopeful that any concerns raised in the investigation will be resolved favorably, leading to an increase in the stock price.

05.00.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care (TNDM) saw a significant increase in its stock value due to various positive factors today:
• The company is part of a group of biotech companies leading advancements in diabetes treatments, moving beyond traditional insulin shots towards functional cures and regenerative medicine, which has captured investor interest and confidence in TNDM's future.
• The anticipated growth of the disposable insulin pumps market, where Tandem Diabetes Care plays a pivotal role, suggests a promising future for the company, with the rising adoption of tubeless patch pumps fueling market expansion.
• Recent updates made by Tandem Diabetes Care to its bylaws to strengthen governance rules illustrate a dedication to transparency and accountability, reassuring investors and potentially attracting new interest in the company.
• Significant purchases of Tandem Diabetes Care stock by key executives indicate a belief in the company's direction and future expansion, offering a positive perspective for investors and contributing to the upward movement in the stock price.

10.11.2025 - TNDM Stock was up 6.1%

• The stock of Tandem Diabetes Care (TNDM) experienced a bullish movement following an analyst's target price increase to $23, leading to a 4.5% jump in the stock price.
• Despite the recent gains and analyst optimism, the stock is still down 43.3% year-to-date and trading below its 52-week high, indicating potential room for growth.
• The company's stock rebounded after a previous drop due to a voluntary medical device correction for select t:slim X2 insulin pumps, showcasing resilience in the face of challenges.
• Analysts are re-evaluating Tandem Diabetes Care's valuation, with some intrinsic value estimates below current levels, but competitive pressures and execution challenges pose risks to future growth and margin assumptions.